Branded as GPX, this new platform represents the next generation of physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software. Utilizing proven top-rated science, advanced models, refined algorithms and integrated machine learning (ML) technology, GPX offers an entirely updated user experience with an intuitive interface, streamlined workflows, and faster processing.
'GPX is truly a culmination of a long-term collaboration with our partners to understand how we can better support their program needs and enable critical scientific thinking,' said
'For more than 25 years, we have remained laser-focused on providing the best science and algorithms on the market. Our commitment to continuous innovation and improvement is why GastroPlus remains the preferred platform for predicting a wide array of applications, including gastrointestinal absorption for oral products, first-in-human outcomes, and food effects,' said
GPX is designed to be a comprehensive PBPK/PBBM modeling and simulation platform, allowing users to handle everything from early discovery high-throughput PK simulations and drug-drug interactions (DDIs) to population predictions and more all in the same place. Utilization of a single PBPK/PBBM platform, with reusable assets and templates, reduces the time spent on tedious tasks like model setup, importing and exporting data, and reformatting plotted modeling results.
GPX offers flexible deployment options, allowing for both local installation and seamless integration with cloud environments, providing users with the freedom to choose the best setup for their needs.
About
Serving clients worldwide for more than 25 years,
Forward-Looking Statements
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like 'believe,' 'expect' and 'anticipate' mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market.
Contact:
Tel: 661-723-7723
Email: renee.bouche@simulations-plus.com
Tel: 310-622-8251
Email: slp@finprofiles.com
(C) 2024 Electronic News Publishing, source